Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
20.92
+0.21 (1.01%)
At close: Dec 5, 2025, 4:00 PM EST
21.31
+0.39 (1.86%)
After-hours: Dec 5, 2025, 7:38 PM EST
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Tandem Diabetes Care stock have an average target of 22, with a low estimate of 12 and a high estimate of 55. The average target predicts an increase of 5.16% from the current stock price of 20.92.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tandem Diabetes Care stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 3 | 4 | 4 | 3 | 3 |
| Hold | 6 | 10 | 10 | 11 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 15 | 16 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 → $23 | Hold | Maintains | $17 → $23 | +9.94% | Dec 2, 2025 |
| Barclays | Barclays | Buy Maintains $51 → $55 | Buy | Maintains | $51 → $55 | +162.91% | Nov 10, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $13 → $17 | Hold | Maintains | $13 → $17 | -18.74% | Nov 10, 2025 |
| Truist Securities | Truist Securities | Hold Reiterates $16 → $17 | Hold | Reiterates | $16 → $17 | -18.74% | Nov 10, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $13 → $14 | Hold | Maintains | $13 → $14 | -33.08% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
1.02B
from 940.20M
Increased by 8.59%
Revenue Next Year
1.13B
from 1.02B
Increased by 10.19%
EPS This Year
-1.88
from -1.47
EPS Next Year
-0.96
from -1.88
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.2B | ||||
| Avg | 1.0B | 1.1B | ||||
| Low | 975.9M | 1.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 12.4% | 16.9% | ||||
| Avg | 8.6% | 10.2% | ||||
| Low | 3.8% | 2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.58 | -0.45 | ||||
| Avg | -1.88 | -0.96 | ||||
| Low | -2.62 | -2.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.